LIC’s shareholding in Dr. Reddy’s Laboratories rose from 5.6% at the end of September 2024 to 6.5% by December 2024, and further to 7.19% as of March 2025, according to the latest shareholding ...

Dr Reddy’s Laboratories announced that it has partnered with Alvotech, to co-develop, manufacture, and sell a biosimilar version of Keytruda (pembrolizumab), for global markets.

Alvotech (ALVO) and Dr. Reddy’s Laboratories (RDY) have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda ...

Bio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, and Dr. Reddy's Laboratories SA, wholly ...

Hyderabad: Dr Reddy's Labs (DRL) on Wednesday said its subsidiary, Dr Reddy's Labs SA, entered into commercialisation and licensing agreements with Ch.

Dr. Mehmet Oz built his television empire on the simple promise that you can take control of your health. Over 13 seasons of “The Dr. Oz Show,” from 2009 to 2022, he told viewers what to eat ...

Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month October 14, 2024 09:47 AM Eastern Daylight Time ...

We believe Dr. Reddy’s is in good financial health. At the end of fiscal 2023, the company had roughly INR 5.8 billion in cash and equivalents and a total debt balance of less than INR 9.0 billion.

Read our review of Dr Reddy's Nerivio device, a smart pain relief solution for migraine. Learn about its design, performance, and how it offers an alternative to migraine medicines.

Dr. Reddy’s Laboratories Ltd. on Wednesday announced that it has acquired the MenoLabs business, a women’s health and dietary supplement branded portfolio from Amyris, Inc. in Amyris ...

New Delhi: Dr Reddy's Laboratories, Glenmark Pharma and Zydus are recalling products in the US market for manufacturing issues, according to the US Food and Drug Administration ().In its latest ...